Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) will be reporting earnings this Tuesday before market hours. Here’s what to expect.
NeoGenomics missed analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $168 million, up 7.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year revenue guidance beating analysts’ expectations.
Is NeoGenomics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting NeoGenomics’s revenue to grow 11.2% year on year to $182.9 million, in line with the 12% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.02 per share.
Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 5 downward revisions over the last 30 days (we track 12 analysts). NeoGenomics has missed Wall Street’s revenue estimates three times over the last two years.
Looking at NeoGenomics’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 15.2%, beating analysts’ expectations by 1.4%, and Labcorp reported revenues up 9.5%, topping estimates by 1%. Quest traded up 2.3% following the results while Labcorp was also up 5.6%.
Read our full analysis of Quest’s results here and Labcorp’s results here.
Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. NeoGenomics is down 10.9% during the same time and is heading into earnings with an average analyst price target of $11.05 (compared to the current share price of $6.51).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
